9 May 2024 - Australians with different types of cardiomyopathies now have access to new treatments under the Pharmaceutical Benefits Scheme.

Tafamidis (Vyndamax) will be listed for the first time to treat transthyretin amyloid cardiomyopathy with New York Heart Association class I-II.

Read Minister for Health press release